依达拉奉联合舒血宁治疗急性脑梗死的临床观察

Clinical Observation on Acute Cerebral Infarction Treated with Edaravone and Shuxuening

目的观察依达拉奉注射液联合舒血宁注射液治疗急性脑梗死的临床疗效和安全性。方法将70例急性脑梗死患者随机分为对照组34例和观察组36例。对照组给予香丹注射液20 mL加生理盐水250 mL静滴,1次/d,连用14 d;观察组给予依达拉奉注射液30 mg加生理盐水100 mL静滴,2次/d,连用14 d;舒血宁注射液20 mL加生理盐水250 mL静滴,1次/d,连用14 d。14 d后,判定两组的临床疗效和进行神经功能缺损评分。结果观察组临床的总有效率为88.9%,优于对照组的67.6%,差异有统计学意义(P<0.05);两组治疗后,神经功能缺损评分均较治疗前显著下降,以观察组下降明显且优于对照组(P<0.05)。结论依达拉奉联合舒血宁注射液治疗急性脑梗死是安全及有效的,值得临床推广应用。

Objective To observe the clinical effect and safety on acute cerebral infarction（ACI） treated with edaravone and shuxuening.Methods 70 cases of such patient were divided into control group（34 cases） and observe group（36 cases）.The control group was treated with 20 mL Xiangdan injection and NS 250mL per day and twice weeks as a course.The observe group was treated with 30 mg edaravone and NS 100 mL,and 20 mL Shuxuening and NS 250 mL for twice weeks.The assessment score of nerve function defect of two group were compared. Results The total effective rate was 88.9%in observe group and 67.6%in control group with significant difference（P〈0.05）.Conclusion This combination use to treat ACI might be safe and effective that could be used in clinic.